Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre hospitalier de l'Université de Montréal (CHUM)
National Cancer Institute (NCI)
Centre Oscar Lambret
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Carilion Clinic
National Cancer Institute (NCI)
Atavistik Bio, Inc
BeOne Medicines
Centre Oscar Lambret
Seagen Inc.
University of Kansas Medical Center
Seagen Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
University of California, Davis
M.D. Anderson Cancer Center
Tesaro, Inc.
Hoffmann-La Roche
Sun Yat-sen University
Sun Yat-sen University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
GOG Foundation
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
University Health Network, Toronto
University Health Network, Toronto
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Yale University
National Cancer Institute (NCI)